Skip to main navigation
  • Home

  • Development Programs

  • VX15 Immuno-Oncology

  • VX15 Neurology

  • VX18 Neurology

  • VX15 Autoimmune

  • NKT Vaccine

  • NKT Vaccine

  • ActivMAb®

  • Vaccinia Display

  • Capabilities

  • Optimization

  • Target Identification

  • Publications

  • News & Publications

    • News

    • Publications

  • Careers

  • Corporate

    • Management

    • Partners

    • Contact

  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events

  • Presentations

  • Home

  • About

  • Corporate Overview

  • Management

  • Partners

  • Pipeline

  • Pepinemab
    Neurology

  • Pepinemab
    Immuno-Oncology

  • Research & Development Programs

  • Clinical Trials

  • Patients

  • Physicians & Researchers

  • News & Publications

    • News

    • Publications

  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events

  • Presentations

  • Careers

  • Contact Us

  • ActivMAb ®

    • Vaccinia

    • Antibody Discovery

    • Antigen Virus

    • Protein Optimization

    • Antigen Discovery

    • Antibody Optimization

    • ActivMAb ® Contact

Science in the service of medicine
  • About
    • Corporate Overview
    • Management
    • Partners
  • Pipeline
    • Pepinemab Neurology
    • Pepinemab Immuno-Oncology
    • Research & Development Programs
  • Clinical Trials
    • Patients
    • Physicians & Researchers
  • News & Publications
    • News
    • Publications
  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events
  • Presentations
  • Careers
  • Contact Us
  • ActivMAb ®
    • Vaccinia
    • Antibody Discovery
    • Antigen Virus
    • Protein Optimization
    • Antigen Discovery
    • Antibody Optimization
    • Contact Us

Investors

  • Investor Overview
  • News Releases
  • Events
  • Presentations
  • Stock Information
  • Corporate Governance
  • Financial Information
  • Investor Services

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • IR Contacts
  • LinkedIn
  • Twitter

Filter by content type

  • (-) News (141)

Filter by form group

Filter by year

  • 2023 (16)
  • 2022 (15)
  • 2021 (18)
  • 2020 (17)
  • 2019 (20)
  • 2018 (11)
  • 2017 (3)
  • 2016 (6)
  • 2015 (13)
  • 2014 (7)
  • 2013 (4)
  • 2012 (3)
  • 2011 (5)
  • 2010 (3)
News

Vaccinex Presented its ActivMAb® Antibody Discovery Technology at the 2014 PEGS Europe Summit

News

Vaccinex Presented data on VX15/2503 at American Society of Clinical Oncology (ASCO) 2014 Conference

News

Vaccinex Appoints Steve Cobourn, C.P.A. as Chief Financial Officer

News

Vaccinex Presented data on VX15/2503 at CRI Cancer Immunotherapy 2013 Conference

News

Vaccinex Presented VX15 Preclinical MS Data at the 2013 ECTRIMS Annual Conference

News

Vaccinex Appoints Valerie Iddison, M.D. as Chief Medical Officer

News

Vaccinex, Inc. Announces Initiation of a Phase 1 Clinical Trial of VX15/2503 Antibody in Multiple Sclerosis Patients

News

Vaccinex Presented Antibody Selection Technology at the 2012 IBC Antibody Engineering and Antibody Therapeutics Conference

News

Vaccinex to Present VX15 and VX5 Preclinical MS Data at the 2012 ECTRIMS Annual Conference

News

Vaccinex Presented at the American Association for Cancer Research (AACR) Annual Conference

Pagination

  • Page 1
  • Next page ››

  • About
  • Pipeline
  • Clinical Trials
  • News
  • Careers
  • Contact
Vaccinex Inc.
1895 Mount Hope Avenue, Rochester, NY 14620
P: 585-271-2700
F: 585-271-2765
info@vaccinex.com
  • © 2023 Vaccinex. All rights reserved
  • |
  • Privacy Policy
  • |
  • Site by Minerva